New nasal spray aims to soothe seasonal allergy misery
NCT ID NCT07219849
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 29 times
Summary
This study tests a new nasal spray called ALDP001 for people with seasonal allergic rhinitis (hay fever). Researchers want to find the best dose and how often to use it to reduce symptoms like sneezing, stuffy nose, and runny nose. About 164 adults will take part, and their symptoms will be tracked over 8 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS (SAR) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cliantha Research
RECRUITINGMississauga, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALDP001 nasal spray
What this could lead to
If successful, this could provide a new treatment option to ease nasal allergy symptoms like sneezing and congestion.
What could go wrong
This is an early Phase 2 trial with only 164 participants, so results may not apply to everyone. The treatment may not work better than a placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.